IceMiller

Daniel Corsaro

Partner

daniel.corsaro@icemiller.com

317 221 2904

Daniel Corsaro practices tax law, focusing on mergers, acquisitions and corporate restructurings. Prior to rejoining Ice Miller, Dan served as a tax partner at a Big 4 public accounting firm in its transaction advisory services practice. For several years, Dan was the leader of the tax group in the portion of that practice that served the U.S. Midwest.

Dan has assisted many firms across the country in a variety of corporate restructurings, taxable asset acquisitions, taxable share acquisitions, tax-deferred asset acquisitions, tax-deferred share acquisitions, initial public offerings, management buyouts, leveraged buyouts, joint ventures, spin-offs and other strategic alliances and financing transactions. Dan's experience extends to a variety of industries, including life sciences, consumer products, private equity, insurance, and manufacturing organizations.

Dan graduated from the University of Notre Dame with a Bachelor of Business Administration in Accounting. He was a licensed Certified Public Accountant in Indiana and earned his juris doctor from The Indiana University Robert H. McKinney School of Law.

Education

- University of Notre Dame (B.B.A, 1986)
- Indiana University Robert H. McKinney School of Law (J.D., 1990)

Admissions

- Indiana

Awards & Honors

- *The Best Lawyers® In America*, Mergers and Acquisitions Law and Tax Law, 2024-2026
- *The Best Lawyers in America*® "Lawyer of the Year" for Tax in Indianapolis, 2026

Services & Industries

- Business

Success Stories

Ice Miller Counsels MEDiC Life Sciences on Acquisition of Clinical-Stage Oncology Program
Ice Miller represented MEDiC Life Sciences, a biotechnology company pioneering next-generation functional genomics in 3D cancer models, in its acquisition of a clinical-stage oncology program. The asset, which has completed Phase Ib trials in more than 70 patients, marks a significant step in MEDiC's strategy to build a robust therapeutic pipeline.

Through its proprietary SLS™ (Synthetic-Lethal-Gene Signature) biomarker platform, MEDiC identified biomarkers that enhance the program's efficacy by more than 100-fold in preclinical cancer models. With these biomarkers being highly prevalent in cancer patients, the company sees both strong therapeutic potential and a compelling market opportunity.

MEDiC plans to advance the program through investigator-sponsored trials, aiming to validate this biomarker-driven strategy in humans. If successful, the initiative would not only deliver a valuable oncology therapy but also demonstrate the broader power of MEDiC's platform approach.

The Ice Miller team advising MEDiC was led by partner TaeSoo Sean Kim, with support from partners Dann Bruno, Daniel Corsaro, Louis DeLucia, and Weihong Hsing from firm's Business, Bankruptcy & Restructuring, Intellectual Property, and Tax practice groups. Paralegal Michal Shomron also provided valuable support. Ice Miller has served as a trusted advisor to MEDiC across multiple stages of its growth, providing legal and strategic counsel in support of its mission to accelerate the development of next-generation cancer treatments.

Ice Miller Represents Voronoi in Sale of RIPK1 Program to Anvia Therapeutics
Ice Miller represented Voronoi, a South Korean public company, in its asset sales agreement with Anvia Therapeutics, a United States-based biotech company funded by Deerfield, one of the leading venture capital investors in the United States life sciences sector.

The transaction grants Anvia rights to VRN04, Voronoi's oral RIPK1-targeting drug candidate under development for autoimmune, chronic inflammatory, and neurodegenerative diseases. The agreement was executed following Anvia's exercise of an option granted to the company in 2024.

Under the terms of the deal, Voronoi will receive up to $14.5 million in upfront and milestone payments, payable in both cash and equity, along with royalty on net sales upon commercialization. As part of the upfront consideration, Voronoi received three million shares of Anvia common stock valued at $3 million. Additional milestone events will trigger further cash payments and share issuances. This transaction highlights the increasing recognition of RIPK1 as a therapeutic target and underscores Voronoi's continued innovation in autoimmune and neuroinflammation therapies.

Ice Miller Business partner TaeSoo Sean Kim led the negotiations, with partners Dann Bruno and Daniel Corsaro assisting on the equity and tax components, respectively.

Ice Miller Client Schrödinger Enters into License and Collaboration Agreement with Novartis
Ice Miller client Schrödinger, Inc. (NASDAQ: SDGR) today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis's portfolio for further development. The companies also announced an expanded three-year software agreement that substantially increases Novartis's access to Schrödinger's computational predictive modeling technology and enterprise informatics platform.

The full press release can be found here.

As part of the agreement, Schrödinger will receive $150 million upfront payment, with eligibility to receive up to approximately $2.3 billion in milestone payments plus royalties on each product commercialized by Novartis.

Ice Miller's rapidly growing Life Sciences team has been counseling Schrödinger since 2022 and continues to support the company in their growth utilizing its computational predictive modeling technology for drug discovery. The Ice Miller deal team was led by Business Group Partner TaeSoo Sean Kim and included Mai Zymaris and Simone Park, with additional deal support from Nancy Kartos and Xuan Feng. Specialist support was provided by Anthony Aaron (Regulatory/Antitrust), Grace Dahm (Regulatory/Antitrust), Daniel Corsaro (Tax), Pierce Han (SEC/Capital Markets), Fabian Koenigbauer (IP), and Ethan Rii (Healthcare).

Ice Miller Represents Forge Biologics in $620M Acquisition by Ajinomoto
Forge Biologics Holdings, LLC, a Columbus, Ohio-based premier gene therapy contract development & manufacturing organization, has been acquired by the Ajinomoto Group, a Japanese multinational food and biotechnology public company, in an all-cash $620M deal.

The Ice Miller deal team was led by Edward Braum and Dann Bruno, with additional corporate support from Erik Olson, Kevin Burns, Ben Goodman, Chris Michael, Chelsea Abramowitz, Brigid Sharek, Huidi Shu, and Lisa Samblanet. Kathleen Scheidt, Dan Corsaro, Nick Casto, Sean Kim, Holly Banta, Cathy Strauss, Anthony Aaron, Grace Dahm, Nick Reuhs, and Brian Harvey provided specialist support.

Ice Miller has represented Forge since its inception in 2020 through its various rounds of venture capital financing, including its $40M Series A financing in 2020, $120M Series B financing in 2021, and $90M Series C financing in 2022. Ice Miller Business Group partners Edward Braum and Sean Kim have represented Forge through its growth, with Ed overseeing the structuring and financing of the company, and Sean facilitating licensing and day-to-day commercial transactions.

This representation further highlights Ice Miller's rapidly growing life sciences practice, with the acquisition placing Forge in a position for long-term growth. The transaction also supports Ajinomoto's desire to extend its development and manufacturing of gene therapies worldwide.

Ice Miller Represents EVE Energy in a $3B Joint Venture for Battery Cell Production in the U.S.
Ice Miller is representing EVE Energy Co., Ltd. (EVE), a global lithium battery company, in a joint venture with Accelera by Cummins, Daimler Truck and PACCAR to build a manufacturing plant in the United States, which is expected to have a range of $2 to $3 billion in total investment. This strategic joint venture will manufacture battery cells for commercial vehicles to help transition into clean energy.

Ice Miller Business Group partners Sean Kim and Edward Braum represent EVE as external counsel, with Sean as lead counsel responsible for overseeing the structuring and negotiation of the transaction. The deal team also includes Simone Park, Huidi Shu, Cody Laska, Josh Borean, Daniel Corsaro, Safet Metjahic, Ming He, Anthony Aaron, Dale Stackhouse, Grace Dahm, John Pence, and Mike Flint.

The location of the manufacturing plant is to be determined.